|Sample:||Urine||Certificate:||ISO, CE, FDA|
|Usage:||Professional Use||Shelf Life:||24 Months|
MDMA Rapid Test Cassette,
ISO Urine Sample Rapid Test Cassette
(MDMA) Methylenedioxymethamphetamine-ecstasy Rapid Test Cassette for Urine Sample
Methylenedioxymethamphetamine-ecstasy (MDMA) Rapid Test is a rapid, screening test for the qualitative detection of Methylenedioxymethamphetamine -ecstasy and metabolites in human urine at specified cut oflevels.
For professional use only.
For in vitro diagnostic use only.
Methylenedioxymethamphetamine-ecstasy (MDMA) Test is an immuno-chromatographic assay for the qualitative determination of the presence of Methylenedioxymethamphetamine-ecstasy (MDMA) listed in the table below.
Methylenedioxymethamphe tamine-ecstasy (MDMA)
tamine HCl (MDMA)
This assay provides only a preliminary analytical test result. Gas Chromatography/Mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to Methylenedioxymethamphetamine -ecstasy (MDMA) of abuse test result, particularly when preliminary positive results are indicated.
MDMA belongs to a family of man-made drugs. Its relatives include MDA (methylenedioxyamphetamine), and MDEA (methylenedioxyethylamphetamine). They all share the amphetamine-like effects. MDMA is a stimulant with hallucinogenic tendencies described as an empathogen as it releases mood-altering chemicals, such as cartooning and L-dopa, and may generate feelings of love and friendliness. The adverse effects of MDMA use include elevated blood pressure, hyperthermia, anxiety, paranoia and insomnia . MDMA is administered either by oral ingestion or intravenous injection. The effects of MDMA begin 30 minutes after intake, peak in an hour and last for 2 – 3 hours.
Methylenedioxymethamphetamine-ecstasy (MDMA) Rapid Test is a competitive immunoassay that is used to screen for the presence of Methylenedioxymethamphetamine-ecstasy (MDMA) and metabolites in urine. It is chromatographic absorbent device in which, drugs within a urine sample, competitively combined to a limited number of drug monoclonal antibody (mouse) conjugate binding sites.
When the test is activated, the urine is absorbed into test by capillary action, mixes with the respective drug monoclonal antibody conjugate, and flows across a pre-coated membrane. When drug within the urine sample is below the detection level of the test, respective drug monoclonal antibody conjugate binds to the respective drug-protein conjugate immobilized in the Test Region (T) of the test . This produces a colored Test line in the Test Region (T) of the , which, regardless of its intensity, indicates a negative test result.
When sample drug levels are at or above the detection level of the test, the free drug in the sample binds to the respective drug monoclonal antibody conjugate, preventing the respective drug monoclonal antibody conjugate from binding to the respective drug-protein conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct colored band in the test region, indicating a preliminary positive result.
To serve as a procedure control, a colored line will appear at the Control Region (C) of , if the test has been performed properly.
【WARNINGS AND PRECAUTIONS】
【STORAGE AND STABILITY】
Test must be in room temperature ( 15ºC to 30ºC)
【INTERPRETATION OF RESULTS】
Preliminary positive (+)
Only one colored band appears, in the control region (C). No colored band appears in the test region (T).
Two colored bands appear on the membrane. One band appears in the control region (C) and another band appears in the test region (T).
Control band fails to appear. Results from any test which has not produced a control band at the specified read time must be discarded. Please review the procedure and repeat with a new test. If the problem persists, discontinue using the kit immediately and contact your local distributor.